Stock Watch: Too Early To Call The End Of Biotech Wilderness
Reports Of Emergence From Biotech’s Dark Age May Have Been Exaggerated
To emerge from a wilderness period or biotech winter where generalist investors shun the sector, biotech’s good news needs to outweigh the bad and be attractively priced. We may not be there yet.
